Drew and colleagues (124) demonstrated that BRCA2-defective PDA cells (CAPAN-1 line) were sensitive to the PARP1 inhibitor AG014699 in vitro and in sub-cutaneous mouse tumors. The gene discussed is PARP1; the disease is Patent ductus arteriosus.